Abstract
Centene will report first-quarter 2026 results on April 28, 2026 Pre-Market; this preview summarizes consensus revenue, margin and EPS expectations, reviews last quarter’s performance, and highlights the segments and catalysts likely to matter most on the print.Market Forecast
Consensus for the current quarter points to revenue of 47.53 billion US dollars, EBIT of 1.35 billion US dollars, and EPS of 2.13, implying year-over-year growth of 9.62% for revenue and 3.65% for EBIT, while EPS is expected to decline 16.43% year over year. Street models embed a margin mix of modest expansion in operating profit but pressure at the per-share line; no explicit consensus gross margin or net margin is available, though models anticipate continued low-single-digit net margin typical of managed care.Centene’s core health insurance and services business remains the primary driver, with management fees and benefit costs underpinning near-term revenue and membership dynamics. The most promising business is insurance and services at 44.73 billion US dollars last quarter; outlook commentary centers on membership mix, premium rate adequacy, and medical cost trends.
Last Quarter Review
Centene’s last reported quarter delivered revenue of 49.73 billion US dollars, a gross profit margin of 7.99%, a GAAP net loss attributable to shareholders of 1.10 billion US dollars, a net profit margin of -2.44%, and adjusted EPS of -1.19, with revenue up 21.86% year over year. Sequential net profit improved by 83.40% versus the prior quarter’s loss pace.Business mix was concentrated in insurance and services at 44.73 billion US dollars and premium taxes at 4.998 billion US dollars, reflecting core Medicaid and Marketplace volumes. The main business highlight was scale expansion in insurance and services, which drove top-line growth despite a negative GAAP margin backdrop and elevated medical cost ratios.
Current Quarter Outlook (with major analytical insights)
Core Insurance and Services
The core insurance and services franchise should anchor the quarter, with consensus revenue growth of 9.62% year over year to 47.53 billion US dollars indicating continued momentum in Medicaid, Marketplace, and Medicare-related programs. Operating leverage is expected to be evident in EBIT, which is modeled at 1.35 billion US dollars, up 3.65% year over year, suggesting improved administrative expense control and scale efficiencies. However, gross margin comparisons are likely to be sensitive to medical cost trends; prior-quarter gross margin of 7.99% provides a baseline, but seasonality and redetermination effects could pressure utilization in the near term. We expect medical cost ratio management and premium rate adjustments to be the key swing factors for the profitability trajectory of the core book.Most Promising Segment
Within the portfolio, the insurance and services line remains the largest and most promising by absolute revenue, printing 44.73 billion US dollars last quarter and likely contributing the lion’s share of growth this quarter. The business benefits from enrollment stability and targeted pricing, though the YoY margin cadence will depend on benefit cost normalization after last year’s uptick. Given consensus EBIT growth and the step-down implied in EPS, we infer higher below-the-line items or share count effects, reinforcing that the segment’s operating performance is intact while non-operating factors may dilute per-share results. Investors should track membership mix, Marketplace retention rates, and risk-adjustment settlements as proximate drivers of incremental upside.Key Stock Price Drivers This Quarter
Medical cost trends and redetermination dynamics are poised to be the dominant drivers of investor reaction. A benign utilization print with stable outpatient and pharmacy trends would support the forecast EBIT improvement, while any acceleration in inpatient or high-cost specialty spend could cap upside. Rate adequacy and bid outcomes for state programs will also color forward guidance; commentary that points to disciplined pricing and contract wins could cushion EPS pressure. Lastly, capital allocation and any updates on share repurchases or balance-sheet positioning may influence per-share metrics and valuation, particularly given the consensus expectation for an EPS decline despite higher EBIT.Analyst Opinions
Across recent commentary, the majority of analysts maintain a constructive stance, emphasizing revenue growth resilience and improving operating profitability despite forecast EPS headwinds. Several well-followed institutions have highlighted that consensus revenue growth near 10% alongside an uptick in EBIT implies execution on medical cost control and SG&A efficiency, which they see as supportive for managed care valuations into mid-2026. The bullish camp argues that membership trends in Medicaid and Marketplace remain favorable relative to earlier redetermination fears, setting up potential upside to margins as utilization normalizes through the year.Analysts pointing to upside also note that valuation screens remain reasonable versus peers when calibrated to operating income rather than per-share metrics, and they expect clarity on rate filings and state contract renewals to reduce uncertainty. The predominant view is that a clean beat on medical cost stability or confirmation of disciplined pricing would be enough to offset near-term EPS optics. In short, the majority opinion is positive: revenue growth, manageable medical cost trends, and incremental operating leverage are expected to underpin the quarter, and management’s color on cost and pricing is seen as the key catalyst for the stock reaction on April 28, 2026.
Comments